GYRE THERAPEUTICS, INC.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
On June 16, 2025 (the “Effective Date”), Weiguo Ye, the Chief Operating Officer of the Company, entered into a Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K) with Futu Securities International (Hong Kong) Limited, a company organized under the laws of Hong Kong SAR (“Futu”). Mr. Ye’s plan appoints Futu to arrange for the sale of up to 700,000 shares of common stock. The trading arrangement terminates 15 months after the Effective Date or upon the sale of all shares pursuant to the trading arrangement. During the three months ended June 30, 2025, no other director or executive officer adopted orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, as such terms are defined under Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.